Skip to content
Screener

Dogwood Therapeutics DWTX Q1 2026 earnings

Reported May 14, 2026 · Before market open

EPS-$0.15Beat by $0.07
EPS estimate-$0.22

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.15

Financials

Q1 2026

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$70.48M-43.2%
Enterprise value$57.39M-46.2%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.9×-1.6×

FAQ

When did Dogwood Therapeutics report Q1 2026 earnings?
Dogwood Therapeutics (DWTX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Dogwood Therapeutics's Q1 2026 revenue and EPS?
Dogwood Therapeutics reported eps of $-0.15 for Q1 2026.
Did Dogwood Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.22 by $0.07.
How did Dogwood Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 96.4% from $-4.21.
Where can I find Dogwood Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-060747) and the 10-Q periodic report (0001104659-26-061938) directly on SEC EDGAR. The filing index links above go to sec.gov.